BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37952243)

  • 1. Fludarabine melphalan versus fludarabine treosulfan for reduced intensity conditioning regimen in allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
    Chichra A; Nayak L; Kothari R; Kalantri S; Bonda A; Gokarn A; Punatar S; Mirgh S; Jindal N; Bagal B; Kannan S; Mathew L; Khattry N
    Int J Hematol; 2024 Jan; 119(1):71-79. PubMed ID: 37952243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
    Braitsch K; Schwarz A; Koch K; Hubbuch M; Menzel H; Keller U; Götze KS; Bassermann F; Herhaus P; Verbeek M
    Ann Hematol; 2022 Jun; 101(6):1311-1319. PubMed ID: 35364726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Treosulfan-Based Conditioning Attractive as a Reduced-Intensity Conditioning Regimen in Korea?
    Kim SH; Ji YS; Yun J; Choi SH; Lim SH; Kim CK; Park SK
    J Korean Med Sci; 2023 Sep; 38(36):e281. PubMed ID: 37698206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Busulfan-fludarabine- or treosulfan-fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties.
    Cseh A; Galimard JE; de la Fuente J; Isgro A; Zecca M; Garwer B; Biffi A; Aljurf M; Sundin M; Belendez C; Locatelli F; Balduzzi A; Lawson S; Sengeloev H; Ifversen M; Saccardi R; Wynn R; Lankester AC; Corbacioglu S; Peters C
    Br J Haematol; 2024 Jan; 204(1):e1-e5. PubMed ID: 37795523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation.
    Ussowicz M
    Drugs Today (Barc); 2020 Jun; 56(6):389-403. PubMed ID: 32525137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Nath K; Peterson K; Brown S; Devlin S; Rodriguez N; Barker J; Giralt S; Gyurkocza B; Jakubowski A; Papadopoulos E; Ponce D; Scordo M; Shah G; Perales MA; Sauter C; Lin A; Dahi PB
    Transplant Cell Ther; 2024 Jan; 30(1):81-92. PubMed ID: 37788792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Busulfan and cyclophosphamide-based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion-dependent thalassemia, even in high risk.
    Mehta P; Kapoor J; Singh A; Yadav N; Singh R; Halder R; Verma M; Agrawal N; Ahmed R; Bhurani D
    Eur J Haematol; 2022 Nov; 109(5):447-457. PubMed ID: 35781894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.
    Kanda J; Long GD; Gasparetto C; Horwitz ME; Sullivan KM; Chute JP; Morris A; Shafique M; Li Z; Chao NJ; Rizzieri DA
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):257-63. PubMed ID: 24269380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
    Truscott L; Pariury H; Hanmod S; Davini M; de la Maza M; Sapp LN; Staples K; Proytcheva M; Katsanis E
    Pediatr Blood Cancer; 2023 Feb; 70(2):e30102. PubMed ID: 36394072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.
    Ahmed S; Ghosh N; Ahn KW; Khanal M; Litovich C; Mussetti A; Chhabra S; Cairo M; Mei M; William B; Nathan S; Bejanyan N; Olsson RF; Dahi PB; van der Poel M; Steinberg A; Kanakry J; Cerny J; Farooq U; Seo S; Kharfan-Dabaja MA; Sureda A; Fenske TS; Hamadani M
    Br J Haematol; 2020 Aug; 190(4):573-582. PubMed ID: 32314807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
    Anderlini P; Saliba R; Acholonu S; Giralt SA; Andersson B; Ueno NT; Hosing C; Khouri IF; Couriel D; de Lima M; Qazilbash MH; Pro B; Romaguera J; Fayad L; Hagemeister F; Younes A; Munsell MF; Champlin RE
    Haematologica; 2008 Feb; 93(2):257-64. PubMed ID: 18223284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.
    Duque-Afonso J; Finke J; Labopin M; Craddock C; Protheroe R; Kottaridis P; Tholouli E; Byrne JL; Orchard K; Salmenniemi U; Hilgendorf I; Hunter H; Nicholson E; Bloor A; Snowden JA; Verbeek M; Clark A; Savani BN; Spyridonidis A; Nagler A; Mohty M
    Bone Marrow Transplant; 2022 Aug; 57(8):1269-1276. PubMed ID: 35568756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity.
    Chen GL; Hahn T; Wilding GE; Groman A; Hutson A; Zhang Y; Khan U; Liu H; Ross M; Bambach B; Higman M; Neppalli V; Sait S; Block AW; Wallace PK; Singh AK; McCarthy PL
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):689-698. PubMed ID: 30300731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
    Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
    Dhere V; Edelman S; Waller EK; Langston A; Graiser M; Connolly EC; Switchenko JM; Esiashvili N; Khan MK
    Leuk Lymphoma; 2018 Apr; 59(4):837-843. PubMed ID: 28782395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.
    Yamashita T; Takami A; Uchida N; Fukuda T; Eto T; Shiratori S; Ota S; Akasaka T; Miyakoshi S; Kondo T; Hidaka M; Kanda J; Atsuta Y; Yano S
    Bone Marrow Transplant; 2020 Oct; 55(10):1955-1965. PubMed ID: 32203256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders.
    Marsh RA; Hebert K; Kim S; Dvorak CC; Aquino VM; Baker KS; Chellapandian D; Dávila Saldaña B; Duncan CN; Eckrich MJ; Georges GE; Olson TS; Pulsipher MA; Shenoy S; Stenger E; Lugt MV; Yu LC; Gennery AR; Eapen M
    J Allergy Clin Immunol; 2022 Mar; 149(3):1097-1104.e2. PubMed ID: 34375618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Quality of Life and Outcomes between Haploidentical and Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.
    Hong S; Rybicki L; Mclellan L; Dabney J; Gerds AT; Rotz SJ; Kalaycio M; Hanna R; Hamilton BK; Majhail NS; Sobecks RM
    Transplant Cell Ther; 2022 Apr; 28(4):217.e1-217.e6. PubMed ID: 35074556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies.
    Shimomura Y; Hara M; Yamamoto H; Uchida N; Kawakita T; Ashida T; Takada S; Ikeda T; Morishige S; Maruyama Y; Wake A; Ichinohe T; Fukuda T; Takanashi M; Atsuta Y; Ishikawa T
    Bone Marrow Transplant; 2021 Jul; 56(7):1691-1699. PubMed ID: 33658646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.